CEP1612, a dipeptidyl proteasome inhibitor, induces p27WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice

Jiazhi Sun, Sangkil Nam, Chang Sun Lee, Benyi Li, Domenico Coppola, Andrew Hamilton, Q. Ping Dou, Saïd M. Sebti

Research output: Contribution to journalArticle

Abstract

The ubiquitin proteasome system is responsible for the proteolysis of important cell cycle and apoptosis-regulatory proteins. In this paper we report that the dipeptidyl proteasome inhibitor, phthalimide- (CH2)8CH-(cyclopentyl) CO-Arg(NO2)-Leu-H (CEP1612), induces apoptosis and inhibits tumor growth of the human lung cancer cell line A-549 in an in vivo model. In cultured A-549 cells, CEP1612 treatment results in accumulation of two proteasome natural substrates, the cyclin-dependent kinase inhibitors p21WAF1 and p27KIP1, indicating its ability to inhibit proteasome activity in intact cells. Furthermore, CEP1612 induces apoptosis as evident by caspase-3 activation and poly(ADP-ribose) polymerase cleavage. Treatment of A-549 tumor-bearing nude mice with CEP1612 (10 mg/kg/day, i.p. for 31 days) resulted in massive induction of apoptosis and significant (68%; P <0.05) tumor growth inhibition, as shown by terminal deoxynucleotidyltransferase-mediated UTP end labeling. Furthermore, immunostaining of tumor specimens demonstrated in vivo accumulation of p21WAF1 and p27KIP1 after CEP1612 treatment. The results suggest that CEP1612 is a promising candidate for further development as an anticancer drug and demonstrate the feasibility of using proteasome inhibitors as novel antitumor agents.

Original languageEnglish (US)
Pages (from-to)1280-1284
Number of pages5
JournalCancer Research
Volume61
Issue number4
StatePublished - Feb 15 2001

Fingerprint

Proteasome Inhibitors
Nude Mice
Apoptosis
Growth
Proteasome Endopeptidase Complex
Neoplasms
Cell Cycle Proteins
Uridine Triphosphate
Apoptosis Regulatory Proteins
DNA Nucleotidylexotransferase
Poly(ADP-ribose) Polymerases
Cyclin-Dependent Kinases
Ubiquitin
CEP 1612
Adenocarcinoma of lung
Caspase 3
Antineoplastic Agents
Proteolysis
Lung Neoplasms
Cell Line

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

CEP1612, a dipeptidyl proteasome inhibitor, induces p27WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice. / Sun, Jiazhi; Nam, Sangkil; Lee, Chang Sun; Li, Benyi; Coppola, Domenico; Hamilton, Andrew; Dou, Q. Ping; Sebti, Saïd M.

In: Cancer Research, Vol. 61, No. 4, 15.02.2001, p. 1280-1284.

Research output: Contribution to journalArticle

Sun, Jiazhi ; Nam, Sangkil ; Lee, Chang Sun ; Li, Benyi ; Coppola, Domenico ; Hamilton, Andrew ; Dou, Q. Ping ; Sebti, Saïd M. / CEP1612, a dipeptidyl proteasome inhibitor, induces p27WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice. In: Cancer Research. 2001 ; Vol. 61, No. 4. pp. 1280-1284.
@article{d9f89af2e9344b31881bc64d88e8462e,
title = "CEP1612, a dipeptidyl proteasome inhibitor, induces p27WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice",
abstract = "The ubiquitin proteasome system is responsible for the proteolysis of important cell cycle and apoptosis-regulatory proteins. In this paper we report that the dipeptidyl proteasome inhibitor, phthalimide- (CH2)8CH-(cyclopentyl) CO-Arg(NO2)-Leu-H (CEP1612), induces apoptosis and inhibits tumor growth of the human lung cancer cell line A-549 in an in vivo model. In cultured A-549 cells, CEP1612 treatment results in accumulation of two proteasome natural substrates, the cyclin-dependent kinase inhibitors p21WAF1 and p27KIP1, indicating its ability to inhibit proteasome activity in intact cells. Furthermore, CEP1612 induces apoptosis as evident by caspase-3 activation and poly(ADP-ribose) polymerase cleavage. Treatment of A-549 tumor-bearing nude mice with CEP1612 (10 mg/kg/day, i.p. for 31 days) resulted in massive induction of apoptosis and significant (68{\%}; P <0.05) tumor growth inhibition, as shown by terminal deoxynucleotidyltransferase-mediated UTP end labeling. Furthermore, immunostaining of tumor specimens demonstrated in vivo accumulation of p21WAF1 and p27KIP1 after CEP1612 treatment. The results suggest that CEP1612 is a promising candidate for further development as an anticancer drug and demonstrate the feasibility of using proteasome inhibitors as novel antitumor agents.",
author = "Jiazhi Sun and Sangkil Nam and Lee, {Chang Sun} and Benyi Li and Domenico Coppola and Andrew Hamilton and Dou, {Q. Ping} and Sebti, {Sa{\"i}d M.}",
year = "2001",
month = "2",
day = "15",
language = "English (US)",
volume = "61",
pages = "1280--1284",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - CEP1612, a dipeptidyl proteasome inhibitor, induces p27WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice

AU - Sun, Jiazhi

AU - Nam, Sangkil

AU - Lee, Chang Sun

AU - Li, Benyi

AU - Coppola, Domenico

AU - Hamilton, Andrew

AU - Dou, Q. Ping

AU - Sebti, Saïd M.

PY - 2001/2/15

Y1 - 2001/2/15

N2 - The ubiquitin proteasome system is responsible for the proteolysis of important cell cycle and apoptosis-regulatory proteins. In this paper we report that the dipeptidyl proteasome inhibitor, phthalimide- (CH2)8CH-(cyclopentyl) CO-Arg(NO2)-Leu-H (CEP1612), induces apoptosis and inhibits tumor growth of the human lung cancer cell line A-549 in an in vivo model. In cultured A-549 cells, CEP1612 treatment results in accumulation of two proteasome natural substrates, the cyclin-dependent kinase inhibitors p21WAF1 and p27KIP1, indicating its ability to inhibit proteasome activity in intact cells. Furthermore, CEP1612 induces apoptosis as evident by caspase-3 activation and poly(ADP-ribose) polymerase cleavage. Treatment of A-549 tumor-bearing nude mice with CEP1612 (10 mg/kg/day, i.p. for 31 days) resulted in massive induction of apoptosis and significant (68%; P <0.05) tumor growth inhibition, as shown by terminal deoxynucleotidyltransferase-mediated UTP end labeling. Furthermore, immunostaining of tumor specimens demonstrated in vivo accumulation of p21WAF1 and p27KIP1 after CEP1612 treatment. The results suggest that CEP1612 is a promising candidate for further development as an anticancer drug and demonstrate the feasibility of using proteasome inhibitors as novel antitumor agents.

AB - The ubiquitin proteasome system is responsible for the proteolysis of important cell cycle and apoptosis-regulatory proteins. In this paper we report that the dipeptidyl proteasome inhibitor, phthalimide- (CH2)8CH-(cyclopentyl) CO-Arg(NO2)-Leu-H (CEP1612), induces apoptosis and inhibits tumor growth of the human lung cancer cell line A-549 in an in vivo model. In cultured A-549 cells, CEP1612 treatment results in accumulation of two proteasome natural substrates, the cyclin-dependent kinase inhibitors p21WAF1 and p27KIP1, indicating its ability to inhibit proteasome activity in intact cells. Furthermore, CEP1612 induces apoptosis as evident by caspase-3 activation and poly(ADP-ribose) polymerase cleavage. Treatment of A-549 tumor-bearing nude mice with CEP1612 (10 mg/kg/day, i.p. for 31 days) resulted in massive induction of apoptosis and significant (68%; P <0.05) tumor growth inhibition, as shown by terminal deoxynucleotidyltransferase-mediated UTP end labeling. Furthermore, immunostaining of tumor specimens demonstrated in vivo accumulation of p21WAF1 and p27KIP1 after CEP1612 treatment. The results suggest that CEP1612 is a promising candidate for further development as an anticancer drug and demonstrate the feasibility of using proteasome inhibitors as novel antitumor agents.

UR - http://www.scopus.com/inward/record.url?scp=0035866355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035866355&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 1280

EP - 1284

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 4

ER -